XML 29 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 11, 2014
Sep. 30, 2015
Mar. 31, 2015
Sep. 30, 2014
Sep. 30, 2015
Dec. 31, 2014
Sep. 23, 2014
Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Accumulated deficit   $ (2,586,214,000)     $ (2,586,214,000) $ (2,494,784,000)    
Stockholders' deficit   (124,569,000)     (124,569,000) (73,770,000)    
Cash and cash equivalents   32,928,000   $ 172,465,000 32,928,000 $ 120,841,000   $ 70,790,000
Principal amount of outstanding debt   185,400,000     185,400,000      
Amount available for future borrowings   30,100,000     30,100,000      
Potential proceeds from the exercise of warrants from February 2012 public offering   9,400,000     9,400,000      
Proceeds from issuance of common stock pursuant to ATM issuance         14,536,000      
License and Collaboration Agreement with Sanofi                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Up-front fee       $ 150,000,000        
Potential milestone payment $ 725,000,000 725,000,000     $ 725,000,000      
Profits and losses sharing percentage 35.00%       35.00%      
Maximum secured loan facility             $ 175,000,000  
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Profits and losses sharing percentage 65.00%       65.00%      
Maximum secured loan facility   175,000,000     $ 175,000,000      
License and Collaboration Agreement with Sanofi | Manufacturing Milestone Events                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Milestone payments earned     $ 50,000,000          
ATM Agreements                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Proceeds from issuance of common stock pursuant to ATM issuance   12,200,000            
ATM Agreements | Maximum                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Offering price of common stock under agreement   37,500,000     37,500,000      
Senior convertible notes due December 31, 2019 | Deerfield | Minimum | Facility Agreement | Less portion of commitment asset                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Available amount of credit facility under covenant restrictions   $ 25,000,000     $ 25,000,000